Is Caplin Point Laboratories the Best Stock in Its Sector? A Look at the Numbers
- October 15, 2026
- Posted by: Ankit Jaiswal
- Category: Market
Caplin Point Laboratories CMP Rs 2,338 (15 Oct 2026). Market cap Rs 17,764 Cr. ROE 17.88%. P/E 26.20x versus Industry P/E 36.77x.
Quick Answer
Caplin Point Laboratories is one of the names investors compare when screening the Healthcare sector, built on a 17.88% return on equity and a P/E of 26.20x against an Industry P/E of 36.77x. Whether Caplin Point Laboratories is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.
Is Caplin Point Laboratories the best stock in its sector? The stock trades on the NSE at Rs 2,338 as of 15 October 2026, within its 52-week range of Rs 1,500.30 to Rs 2,990.00. Caplin Point Laboratories Ltd, based in Chennai, is a pharmaceutical company that makes and markets generic formulations, with a strong presence in Latin America and francophone Africa.
Caplin Point Laboratories sits in the Healthcare sector, and its 17.88% ROE and 26.20x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Caplin Point Laboratories
Caplin Point Laboratories Ltd, based in Chennai, is a pharmaceutical company that makes and markets generic formulations, with a strong presence in Latin America and francophone Africa. It also makes sterile injectables for regulated markets through its subsidiary Caplin Steriles. The stock trades about 22 percent below its 52-week high and about 56 percent above its 52-week low. At a market capitalisation of Rs 17,764 Cr, it is tracked as part of the Healthcare sector on Univest.
Is Caplin Point Laboratories the Best Stock in Its Sector?
Caplin Point Laboratories makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 17.88% ROE with a 26.20x P/E against the sector’s 36.77x Industry P/E. Caplin Point Laboratories’ 26.20x P/E is below the 36.77x Industry P/E, Ajanta Pharma at 36.31x and Ipca Laboratories at 35.31x, while its 17.88% ROE is lower than Ajanta Pharma at 23.33%, though higher than Ipca Laboratories at 14.15%, and its debt to equity ratio of 0.00 is below Ajanta Pharma at 0.06 and Ipca Laboratories at 0.10.
| Metric | Caplin Point Laboratories |
|---|---|
| CMP (NSE) | Rs 2,338.20 |
| 52-Week High / Low | Rs 2,990.00 / Rs 1,500.30 |
| Market Cap | Rs 17,764 Cr |
| P/E (TTM) vs Industry P/E | 26.20x vs 36.77x |
| P/B | 5.27 |
| ROE | 17.88% |
| EPS (TTM) | Rs 89.20 |
| Dividend Yield | 0.34% |
| Debt to Equity | 0.00 |
Compare Caplin Point Laboratories Against Other Healthcare Sector Stocks
How Caplin Point Laboratories Compares Against Its Healthcare Sector Peers
The table below sets Caplin Point Laboratories against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Caplin Point Laboratories | 17,764 | 26.20 | 17.88% | 0.00 |
| Ajanta Pharma | 41,211 | 36.31 | 23.33% | 0.06 |
| Ipca Laboratories | 48,550 | 35.31 | 14.15% | 0.10 |
| Peer average (2 companies) | – | 35.81 | 18.74% | 0.08 |
Against this peer set, Caplin Point Laboratories’ 17.88% ROE is below the 18.74% peer average, and its P/E of 26.20x runs below the peer average of 35.81x. Caplin Point Laboratories’ 26.20x P/E is below the 36.77x Industry P/E, Ajanta Pharma at 36.31x and Ipca Laboratories at 35.31x, while its 17.88% ROE is lower than Ajanta Pharma at 23.33%, though higher than Ipca Laboratories at 14.15%, and its debt to equity ratio of 0.00 is below Ajanta Pharma at 0.06 and Ipca Laboratories at 0.10.
What Makes Caplin Point Laboratories Worth Watching in Healthcare
- Valuation: A 26.20x P/E is below the 36.77x Industry P/E, Ajanta Pharma at 36.31x and Ipca Laboratories at 35.31x.
- Returns: A 17.88% ROE is lower than Ajanta Pharma at 23.33%, though higher than Ipca Laboratories at 14.15%.
- Leverage: A debt to equity ratio of 0.00 is below Ajanta Pharma at 0.06 and Ipca Laboratories at 0.10.
Caplin Point Laboratories Valuation: Is It Justified?
Caplin Point Laboratories’ 26.20x P/E is below the 36.77x Industry P/E, Ajanta Pharma at 36.31x and Ipca Laboratories at 35.31x, while its 17.88% ROE is lower than Ajanta Pharma at 23.33%, though higher than Ipca Laboratories at 14.15%, and its debt to equity ratio of 0.00 is below Ajanta Pharma at 0.06 and Ipca Laboratories at 0.10. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is Oracle Financial Services Software the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Caplin Point Laboratories and other Healthcare sector stocks.
How to Track Caplin Point Laboratories Before You Invest
Before deciding whether Caplin Point Laboratories deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.
- Open the Univest Screener and search for Caplin Point Laboratories to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
- Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Caplin Point Laboratories earns a place in the best stock in its sector conversation on the strength of a 17.88% ROE and a P/E of 26.20x against a 36.77x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Caplin Point Laboratories the best stock in its sector?
Ans. There is no single definitive answer, because the best stock in a sector depends on whether an investor is prioritising returns, valuation or balance sheet strength. Caplin Point Laboratories has a 17.88% ROE and trades at 26.20x P/E against a 36.77x Industry P/E. Against the 2 peers compared in this article, its ROE is below the 18.74% peer average and its P/E is below the 35.81x peer average. Its debt to equity ratio of 0.00 is below the 0.08 peer average, which matters because borrowing can inflate returns and add risk when business conditions weaken. These figures are best read together rather than in isolation, and they work as a starting point for your own research and not as a verdict.
What is the current share price of Caplin Point Laboratories?
Ans. Caplin Point Laboratories was trading at Rs 2,338.20 on the NSE as of 15 October 2026, within its 52-week range of Rs 1,500.30 to Rs 2,990.00. The stock trades about 22 percent below its 52-week high and about 56 percent above its 52-week low. Its market capitalisation is Rs 17,764 Cr and its EPS (TTM) is Rs 89.20, which is the earnings figure behind the 26.20x P/E. Share prices change through the trading day, so check the live quote on Univest before acting on any number here.
What sector does Caplin Point Laboratories belong to?
Ans. Caplin Point Laboratories is classified under the Healthcare sector on Univest, and that group of listed companies is the reference point for the 36.77x Industry P/E used in this article. The 2 named peers compared here are Ajanta Pharma and Ipca Laboratories, chosen as comparable listed names so that the P/E, ROE and debt figures come from the same live data source. Investors who want a wider view can compare more Healthcare sector stocks on the Univest Screener.
How does Caplin Point Laboratories compare to its sector peers on P/E?
Ans. Caplin Point Laboratories’ P/E of 26.20x is below the 35.81x average of the 2 named peers, with Ajanta Pharma at 36.31x and Ipca Laboratories at 35.31x. It also sits below the 36.77x Industry P/E, which is the benchmark for the wider Healthcare sector. A P/E that is below a peer average can reflect a valuation discount or premium, but it can also reflect different growth or return expectations, so it should be read alongside ROE and debt. Its P/B ratio of 5.27 gives one more view of how the market values its book value.
What is Caplin Point Laboratories’ return on equity?
Ans. Caplin Point Laboratories reported a return on equity of 17.88%, which is below the 18.74% average of its named peers, with Ajanta Pharma at 23.33% and Ipca Laboratories at 14.15%. ROE shows how much profit a company generates on every rupee of shareholders’ equity, so a higher figure generally points to more efficient use of capital. ROE is easier to trust when leverage is modest, and here the debt to equity ratio is 0.00 against a peer average of 0.08. It is worth checking whether the ROE has been stable over several years rather than relying on a single reading.
Should I invest in Caplin Point Laboratories based on its sector position?
Ans. Sector position is only one input into an investment decision. Caplin Point Laboratories has a 17.88% ROE and a 26.20x P/E, which make it worth researching further, and its dividend yield is 0.34%. You should also weigh its business outlook, earnings consistency, debt levels, your investment horizon and your own risk appetite before buying. Spreading money across several stocks and sectors reduces concentration risk, and this article is educational content, not investment advice. For personalised guidance, consult a SEBI-registered advisor.
